{"links":{"html":"https://www.erudio.com/reports/mslt-ii-nct00297895","json":"https://www.erudio.com/reports/mslt-ii-nct00297895.json","markdown":"https://www.erudio.com/reports/mslt-ii-nct00297895.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"mslt-ii-00297895"}},"request":"https://www.erudio.com/contact?report=mslt-ii-00297895"},"offer":{"cited_commentary_sources":36,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":10,"optional":true,"price_per_verified_person_usd":15,"price_usd":150,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"mslt-ii-nct00297895"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=mslt-ii-00297895","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/mslt-ii-nct00297895","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"standard","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-08T00:48:21.930953Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":11,"coverage":"discussed","id":"A1","source_count":6,"title":"Completion dissection versus active nodal observation"},{"claim_count":9,"coverage":"discussed","id":"A2","source_count":6,"title":"Survival, regional control, and prognostic information"},{"claim_count":9,"coverage":"discussed","id":"A3","source_count":5,"title":"Clinical nodal status and response-directed next steps"},{"claim_count":18,"coverage":"discussed","id":"A4","source_count":6,"title":"Ultrasound expertise, access, and addition to CT/PET"},{"claim_count":16,"coverage":"discussed","id":"A5","source_count":7,"title":"Adjuvant treatment, low-volume disease, and observation choices"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":1,"title":"Transplant and immune-risk constraints"},{"claim_count":22,"coverage":"discussed","id":"A7","source_count":8,"title":"Sentinel-node biopsy value and potential replacements"},{"claim_count":23,"coverage":"discussed","id":"A8","source_count":3,"title":"Follow-up intensity, timing, and imaging work-up"},{"claim_count":14,"coverage":"discussed","id":"A9","source_count":9,"title":"Morbidity, basin-specific surgery, and patient function"},{"claim_count":17,"coverage":"discussed","id":"A10","source_count":6,"title":"Head-and-neck and vulvar extrapolation"},{"claim_count":24,"coverage":"discussed","id":"A11","source_count":4,"title":"Microscopic burden, pathology, and subgroup interpretation"},{"claim_count":32,"coverage":"discussed","id":"A12","source_count":9,"title":"Adoption, patient information preferences, and follow-up ownership"}],"counts":{"cited_sources":36,"claims_by_expression_type":{"comparison":70,"experience":44,"interpretation":117,"opinion":56,"primary_context":1,"question":68,"restatement":92,"uncertainty":35,"unspecified":16},"claims_by_kind":{"attributed_opinion":2,"counterview":4,"interpretation":59,"limitation":18,"source_observation":416},"evidence_units":287,"findings":12,"people_cited":35,"people_identity_verified":10,"people_total":23,"screened_sources":37,"verified_claims":499},"depth":"rich","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"Avoiding routine completion dissection is the leading reading, but regional control and selective exceptions remain"},{"id":"F2","title":"Clinical nodal presentation is a critical boundary; imaging can make that boundary less straightforward"},{"id":"F3","title":"Expert ultrasound and reliable follow-up are conditions of de-escalation, but routine ultrasound alongside CT/PET is contested"},{"id":"F4","title":"Omitting dissection does not settle the adjuvant-treatment decision, particularly in lower-risk disease"},{"id":"F5","title":"Transplant-related constraints can produce a different local-treatment choice without proving a dissection benefit"},{"id":"F6","title":"The completion-dissection result is not read as a reason to abandon sentinel-node biopsy"},{"id":"F7","title":"Follow-up intensity is pragmatic and risk-sensitive; benefit from earlier systemic treatment remains an open question"},{"id":"F8","title":"Imaging should change a decision, but baseline timing and postoperative interpretation can also delay care"},{"id":"F9","title":"Surgical morbidity is a major rationale, but its weight varies by basin, occupation, and patient circumstances"},{"id":"F10","title":"Head-and-neck and vulvar discussions retain site-specific qualifications rather than a blanket extrapolation"},{"id":"F11","title":"Small deposits, assay differences, and nonsentinel-node ascertainment complicate risk interpretation"},{"id":"F12","title":"Implementation includes institutional variation, patient preferences, care ownership, and research infrastructure"}],"medical_affairs_question":"How should Medical Affairs distinguish survival, regional-control, prognostic-information, and morbidity considerations in explanations of surgical de-escalation?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Avoiding routine completion dissection is the leading reading, not a no-benefit or no-care rule"},{"id":"section-2","level":2,"title":"2. Clinical nodal presentation limits the omission message"},{"id":"section-3","level":2,"title":"3. Surveillance quality and incremental ultrasound value are different controversies"},{"id":"section-4","level":2,"title":"4. Adjuvant therapy after omitted dissection remains a separate, preference-sensitive decision"},{"id":"section-5","level":2,"title":"5. A transplant case illustrates treatment constraints, not proof that dissection improves outcomes"},{"id":"section-6","level":2,"title":"6. Sentinel-node biopsy remains distinct from completion dissection"},{"id":"section-7","level":2,"title":"7. Earlier detection is desired, but surveillance schedules and treatment-timing benefits are not settled"},{"id":"section-8","level":2,"title":"8. Baseline and postoperative imaging should clarify management, not merely generate abnormalities"},{"id":"section-9","level":2,"title":"9. Morbidity is important, but not everyone assigns it the same weight"},{"id":"section-10","level":2,"title":"10. Rare-site extrapolation requires its own qualifications"},{"id":"section-11","level":2,"title":"11. Overall confidence coexists with pathology and subgroup uncertainty"},{"id":"section-12","level":2,"title":"12. Implementation is institutional, multidisciplinary, and preference-sensitive"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, na"},"identity":{"accepted_at":"2026-10-08T00:48:21.930953Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-07T22:54:07Z","record_hash":"09870272522b034359f3a0a5e76ce93f9b2437887cd2387f87d3c3df77d7693a","release_hash":"7cdbb8b6dae03d3d7e7c995ff85ea5d0cef74562f4404baa4655d89008213300","report_id":"erudio-nct00297895","run_id":"88b3d4f3-a948-4ddf-8c14-78dbbcfabe22","schema_version":"5.0","slug":"mslt-ii-00297895","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MSLT-II centers on whether patients with skin melanoma and a positive sentinel node, but no clinically apparent nodal disease, need further node surgery or can instead undergo ultrasound surveillance. Clinicians discuss survival and regional control, surgical harms, ultrasound expertise and access, CT/PET imaging, adjuvant-treatment evidence and toxicity, transplant-related risks, microscopic deposits and pathology, sentinel-node biopsy’s role, site-specific applicability, patient preferences, and follow-up coordination.","meta_description":"37 HCP sources screened · 499 verified claims from 36 sources · 12 findings. Updated 2026-10-08.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-bd0a035a92375937926f-df44e180"],"id":"F3","paraphrase":"An X thread asked what extra value routine nodal ultrasound offers for sentinel-node-positive patients already receiving CT/PET surveillance.","source_channel":"x_thread","source_date":"2026-05-27","title":"Expert ultrasound and reliable follow-up are conditions of de-escalation, but routine ultrasound alongside CT/PET is contested"},{"cited_claim_ids":["claim-71f2992a457ca46568e6"],"id":"F4","paraphrase":"A podcast speaker asked what benefit adjuvant PD-1 therapy offers in stage III melanoma when completion lymph-node dissection has been omitted.","source_channel":"podcast","source_date":"2024-12-10","title":"Omitting dissection does not settle the adjuvant-treatment decision, particularly in lower-risk disease"}]},"publication":{"approved_at":"2026-10-07T22:54:07Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-08T08:14:00Z","summary":"Trial study IDs and short name taken from the registry record"},{"affected_ids":[],"date":"2026-10-08T20:30:00Z","summary":"Duplicate cards for the same person were combined"},{"affected_ids":[],"date":"2026-10-09T20:08:00Z","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":34,"refresh_due_at":"2026-10-09T00:48:21.930953Z","retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:indexed_source_unreadable:podcast:episode_id:bf9ae0:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:podcast:episode_id:c0ee60:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:_YII38fS4d8:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:scribe_unavailable:mcp:podcast:04e1e5: diarized re-transcription failed; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:podcast:4b627a: diarized re-transcription failed; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:youtube:WPcuTIZLhVA: diarized re-transcription failed; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:podcast:700130: diarized re-transcription did not finish within the wait cap; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:podcast:7650a6: diarized re-transcription did not finish within the wait cap; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:youtube:xcbpJInWJek: diarized re-transcription did not finish within the wait cap; quotes use the discovery transcript.","commentary:source_uncertainty:mcp:podcast:700130@38489:41311,mcp:podcast:700130@41313:44164: The transcript passage does not provide speaker spans or another source-level decision binding the first-person responses to a named speaker. The surrounding discussion names Professor Long but does not by itself prove who delivered these exact turns; the added claims therefore remain unnamed. Keep the commentary attributed to an unnamed responding speaker unless source-level turn attribution becomes available.","commentary:source_uncertainty:mcp:youtube:WPcuTIZLhVA@55781:57724: The transcript wording about immunotherapy for the identified low-volume groups does not establish whether treatment is sometimes omitted or administered. Retain the exception and qualify the treatment action as unclear; do not infer either action.","commentary:held_out:mcp:podcast:e6db2d@3562:3971,mcp:podcast:e6db2d@2985:3560: a claim calls the owner of the reported surgical view unnamed, although mcp:podcast:e6db2d@2985:3560 explicitly asks about Don Morton's aphorisms and mcp:podcast:e6db2d@3562:3971 answers that question. The adjacent exchange establishes whose view Mark Faries is reporting.","commentary:held_out:mcp:youtube:SADjK_xrpbM@0:1944,mcp:youtube:SADjK_xrpbM@1946:3523: a claim describes an unspecified option and says its referent is unavailable. mcp:youtube:SADjK_xrpbM@0:1944 immediately discusses CLND being obsolete and excluded from guidelines; mcp:youtube:SADjK_xrpbM@1946:3523 then gives the selective exception for that procedure. The supplied context identifies the option as completion lymph-node dissection.","commentary:held_out:mcp:podcast:64356d@2407:2966: Sydney Ch’ng's explicit surveillance trade-off—early recurrence detection against cost, radiation exposure and patient anxiety—is absent from the inventory and its quotations. The existing identifying citations retain only the preceding pragmatic-guidelines sentence.","commentary:held_out:mcp:podcast:64356d@43008:44157: Sydney Ch’ng supplies an institutional, risk-stratified surveillance schedule, including stage IIIA with a sentinel deposit below 1 mm, and anticipates modification according to neoadjuvant pathological response. This distinct practice account is not retained; other speakers' schedules do not substitute for it.","commentary:held_out:mcp:podcast:64356d@44159:44984,mcp:podcast:64356d@44986:45115,mcp:podcast:64356d@45117:45187: The responding speaker says routine PET at every scan is very rarely their practice and confirms whole-body CT as the alternative, reserving PET for particular clinical scenarios. This conditional modality preference is absent.","commentary:held_out:mcp:podcast:64356d@46155:47260: The speaker questions excessive scan frequency because adjuvant patients' dynamic risk changes while fixed schedules do not, and argues for concentrating resources on patients at greatest risk. This is a consequential counterview to intensive surveillance, not merely another schedule.","commentary:held_out:mcp:podcast:64356d@45337:45923: The connected modality-choice reply compares radiation burden for diagnostic CT, PET with low-dose CT, and PET plus diagnostic CT, while explaining the loss of intravenous-contrast information with the lower-dose option. Neither that comparative trade-off nor its qualification is retained.","commentary:held_out:mcp:podcast:64356d@47477:48091: Kevin London says imaging can be either strongly anxiety-provoking or reassuring and that individual patient responses must inform surveillance protocols. a claim's inconvenience question does not retain this distinct patient-support qualification.","commentary:held_out:mcp:podcast:700130@41313:44164,mcp:podcast:700130@44166:47009: The adjuvant treatment-decision exchange explicitly raises dabrafenib/trametinib for resected BRAF-mutant stage III disease, particularly when immunotherapy is contraindicated or its toxicities are unacceptable. The response preserves an unproven extrapolation from metastatic immunotherapy outcomes, irreversible immune toxicities and the difficulty of completing targeted therapy because of fevers. This connected alternative and its reasons are absent.","commentary:held_out:mcp:podcast:9a8ead@7800:8314,mcp:podcast:9a8ead@8682:8864: Ryann Quinn says patients with less than 1 mm of nodal involvement are often excluded from some adjuvant trials, have better prognosis than other stage III patients, and may have better prognosis than stage IIB/IIC patients. These qualifications directly affect applying systemic-treatment evidence after a positive sentinel node and are absent.","commentary:held_out:mcp:podcast:9a8ead@8316:8680: Ryan Elsey gives a separate low-volume stage IIIA example—primary invasion below 2 mm, no ulceration and nodal involvement below 1 mm—with his estimate of greater than 90% five-year disease-free survival. The report's other lower-risk cases and unclear 12% measure do not retain this source-specific risk framing.","commentary:held_out:mcp:podcast:9a8ead@13468:14779,mcp:podcast:9a8ead@15312:15772: Elsey connects adjuvant benefit primarily to stage IIIB–IIID and stage IIIA with nodal involvement above 1 mm, distinguishes recurrence-free from overall-survival benefit, and judges the adjuvant doublet's toxicity unjustified by the benefit described. This is a distinct treatment-selection and withholding rationale absent from the inventory.","commentary:held_out:mcp:podcast:9a8ead@14781:15310,mcp:podcast:9a8ead@15774:16135,mcp:podcast:9a8ead@16496:16990: Quinn describes one-year adjuvant pembrolizumab or nivolumab, says the ipilimumab/nivolumab regimen is too toxic for their adjuvant practice, and states that BRAF V600E/V600K patients may instead receive dabrafenib/trametinib, with no head-to-head superiority answer and choices based on toxicity and preference. This connected treatment-choice view is absent.","commentary:held_out:mcp:podcast:9a8ead@27980:29838: Elsey describes surveillance as variable between countries and evolving because melanoma is uncommon and effective metastatic options are relatively recent. He supplies his account of follow-up duration, broad NCCN intervals and locally determined ESMO practice. This distinct evidence-generation and implementation account is absent.","commentary:held_out:mcp:podcast:c69260@6518:7316: a claim selects the value of a positive sentinel result, but the same unit also explains that a negative result after prior excision is more credible for stereotyped distal-limb drainage than for torso or complex head-and-neck reconstruction, where Cohen may recommend additional surveillance. That consequential diagnostic qualification is absent from all claims and quotations.","commentary:held_out:mcp:podcast:c69260@17248:19077: Holder's response to failed localization describes repeating the injection, allowing time and massage, an approximate personal success rate, selected very elderly patients with good performance status and anticipated longevity, and limited value of SPECT/CT after failed planar localization. These conditions for obtaining otherwise missing nodal information are absent.","commentary:held_out:mcp:podcast:c69260@19079:19696: Cohen describes additional localization attempts and, if mapping still fails without an anatomical explanation, a patient discussion about proceeding without sentinel biopsy or rescheduling surgery. This conditional choice to act or defer is absent.","commentary:held_out:mcp:podcast:c69260@19698:20115,mcp:podcast:c69260@20117:20892: The access-dependent reply says lymphoscintigraphy can be performed the previous day with nuclear-medicine dose adjustment, or omitted for selected limb procedures using a handheld probe; Cohen is hesitant to proceed without it for head-and-neck or torso lesions. The report discusses access and mapping but omits these selective alternatives.","commentary:held_out:mcp:podcast:fbe33a@5245:6045: Georgina Long AO explicitly says sentinel-node biopsy should not be a gatekeeper to adjuvant immunotherapy access, while preserving its important prognostic role in informed benefit-risk discussion. This named view is absent despite the report's extensive synthesis of biopsy value and treatment access.","commentary:held_out:mcp:podcast:fbe33a@6047:8460: The responding speaker explains that generally well-tolerated anti-PD-1 therapy still carries irreversible endocrine risks, and that nodal prognostic information changes the risk-benefit conversation and patients' appetite for toxicity. This rationale is not retained by the later stage IIIA access claims.","commentary:held_out:mcp:podcast:fbe33a@8462:8878: The speaker acknowledges international disagreement and a push to abandon sentinel biopsy, while stating their view that doing so requires a better recurrence-prediction test. This dissent and condition are absent.","commentary:held_out:mcp:podcast:fbe33a@9102:10323: The speaker permits a selective exception to sentinel biopsy when a patient will choose drug therapy on the known baseline risk regardless of further staging, while favoring biopsy when the patient wants additional prognosis to weigh drug risks. This consequential reason for withholding a procedure is absent from the report's biopsy discussion.","commentary:held_out:mcp:podcast:fbe33a@12481:13302: John Thompson AO emphasizes that the adjuvant trial population was pathologically staged and that patients thought to have stage IIB/IIC may instead have stage III disease without sentinel-node assessment. This is a distinct population-binding qualification to transferring treatment evidence.","commentary:held_out:mcp:podcast:fbe33a@13761:15257,mcp:podcast:fbe33a@15486:15562,mcp:podcast:fbe33a@15564:15823,mcp:podcast:fbe33a@16172:16251,mcp:podcast:fbe33a@16348:16453,mcp:podcast:fbe33a@16546:16634,mcp:podcast:fbe33a@16717:16814: Thompson's estimate of regional-control benefit from sentinel biopsy in the adjuvant era is absent, including the T3b/T4 scope, approximately 27% versus 9% regional recurrence estimates, an adjacent challenge to the evidence source, and his repeated clarification that these are rough extrapolations without trial data. The estimates must not be detached from those caveats.","commentary:held_out:mcp:podcast:fbe33a@18635:19911: The respondent says available data do not establish whether adjuvant immunotherapy prevents regional and distant recurrence equally, notes the preceding sentinel procedures may influence the observed pattern, and gives a biological argument against inherently poorer regional prevention. This qualified interpretation is absent.","commentary:held_out:mcp:podcast:fbe33a@19913:20324: Thompson cautions that neither sentinel positivity nor negativity determines distant-metastasis outcome absolutely, while calling status the best available guide. This qualification to prognostic use is absent.","commentary:held_out:mcp:podcast:fbe33a@20570:22691,mcp:podcast:fbe33a@22693:23285: The connected adjuvant-versus-treatment-at-recurrence reply questions whether early therapy saves more lives than later salvage, explains why modern crossover and effective stage IV options may obscure overall-survival differences, and weighs fear of recurrence and potentially catastrophic recurrence against increasingly early surveillance detection. This fuller rationale is absent from the retained observation option.","commentary:held_out:mcp:podcast:fbe33a@31568:34001,mcp:podcast:fbe33a@34003:34481: The resected stage III treatment-choice reply describes similar initial recurrence reductions with anti-PD-1 and BRAF/MEK therapy, a possible longer-term immunotherapy advantage that is explicitly unproven and cross-trial, irreversible immune toxicity, and preference for BRAF/MEK when immunotherapy is contraindicated in eligible BRAF V600 patients. This distinct comparative choice is absent.","commentary:held_out:mcp:podcast:fd7c8a@4361:6001: Sapna Patel specifically questions adjuvant benefit in stage IIIA because the relevant trial subsets were small and confidence intervals crossed 1, and notes that this microscopic-node, nonulcerated-primary population was not clearly selected for adjuvant therapy even in the interferon era. a claim's unclear risk figure does not retain this evidence-based uncertainty.","commentary:held_out:mcp:podcast:f610f2@11205:13363: In the stage III adjuvant discussion, Hamid says treatment is single-agent rather than LAG-3/PD-1 combination, citing his account of a negative adjuvant stage III/IV comparison. The inventory retains his MSLT3 comments from this unit but not this separate reason against adjuvant combination treatment.","commentary:held_out:mcp:podcast:f610f2@13365:15427: Hamid's adjuvant BRAF-versus-PD-1 response describes one-year treatment and persistent recurrence-free separation, then qualifies targeted-therapy discussions by mutation subtype and his interpretation of V600K results. These conditions are absent from the broader adjuvant-choice inventory.","commentary:held_out:mcp:podcast:64356d@9327:11540: London explains that technical mapping, procurement or pathology failures can compromise a negative sentinel biopsy and says targeted nodal imaging is particularly relevant when the procedure was compromised. This clinical work-up limitation is absent from the retained ultrasound and staging views.","commentary:held_out:mcp:podcast:e6db2d@25950:26862,mcp:podcast:e6db2d@26941:28892: Faries argues that sentinel biopsy can reveal occult stage III disease, change adjuvant counseling and prevent later nodal surgery, while allowing an exception for a very elderly patient with advanced Alzheimer's disease. He also qualifies the uncertain regional effect of adjuvant PD-1. This connected explanation of why nodal information changes subsequent treatment is absent.","commentary:held_out:mcp:podcast:e6db2d@29177:30365: James Larkin says his UK institution still offers and discusses sentinel biopsy for thick primaries and rejects waiting-list pressure alone as a reason to omit it, arguing that the patient-appropriate decision should precede finding resources to deliver it. a claim's cost agreement does not retain this distinct access-dependent policy challenge."],"source_count":37,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","For 6 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.","34 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","3 further source limits are recorded in the machine-readable scope of this record.","The reviewed material is not representative of all clinicians or all public commentary. Additional potentially relevant recordings were unavailable, and unnamed or differently transcribed trial references may be missing.","Overlapping releases and podcast/video versions cannot be counted as independent HCP opinions. Source volume does not establish consensus.","Some passages do not establish who spoke. Their full views remain attributed to unnamed speakers rather than to people listed in programs or participant information.","Some transcript wording remains uncertain. The low-volume immunotherapy passage does not establish whether treatment is omitted or administered, and the case summary does not clearly establish steroid exposure.","Reported guideline positions, approval access, study eligibility, endpoint summaries, and practice changes are dated speaker accounts unless expressly identified as verified contextual reporting. Differing retellings have not been silently reconciled.","Individual cases, small series, retrospective comparisons, biological hypotheses, and speculative subgroup explanations do not establish comparative efficacy or a surgery-benefit subgroup.","The complete later regional-control publication was unavailable; its supplied context should not be read as a complete assessment of that publication.","Professional profiles provide context, not passage attribution or additional evidentiary weight. Meredith Gunder, MD's clinical role is unresolved in the supplied professional context."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":21,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":10},"by_evidence_role":{"commentary":36},"count":36,"evidence_window":{"end":"2026-07-29","start":"2015-11-03"},"retrieval_snapshot":"2026-10-07T22:43:19.819916Z","timeline":[{"count":1,"week":"2015-W45"},{"count":1,"week":"2017-W23"},{"count":1,"week":"2018-W06"},{"count":1,"week":"2019-W39"},{"count":1,"week":"2020-W33"},{"count":1,"week":"2022-W10"},{"count":1,"week":"2023-W05"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2023-W15"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W40"},{"count":1,"week":"2023-W41"},{"count":1,"week":"2023-W52"},{"count":1,"week":"2024-W05"},{"count":1,"week":"2024-W18"},{"count":2,"week":"2024-W29"},{"count":2,"week":"2024-W36"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W01"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W39"},{"count":2,"week":"2026-W02"},{"count":2,"week":"2026-W08"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W31"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT00297895:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00297895:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00297895:protocol:1","quote_policy":"short_quote_link_out"},{"id":"pubmed:28591523","quote_policy":"short_quote_link_out"},{"id":"pubmed:35921122","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:04e1e5","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:16cfb7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3696d5","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4b627a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5784d7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:64356d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:693c0c","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6a65c7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:700130","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:72d010","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7650a6","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8d8da2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9a8ead","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a5fb3a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b470cf","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c69260","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:df0c4b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e6db2d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f610f2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fbe33a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fce303","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fd7c8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1502674694918529027:e2b9a671-9c84-4090-919d-7e2892446a69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1620755333953241088:7a7a665a-0042-4346-861b-b3d74dd437d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1629111979477696513:c88aff45-1d08-43c6-86e8-5c520e7f133f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1874908567699919196:6ddc38f4-c600-4583-a137-50468c6e5a52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059592591092380059:7fe13ec5-f67a-430c-bc2b-d4ea994417da","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ILEoe9z8kzo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JqlNvSo4TvA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:OY7imbfIkNk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SADjK_xrpbM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WPcuTIZLhVA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ezggSNQVQs4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mUT_LJTmUnY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:nKYsNB0ZfZk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qA4muTiAlZA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xcbpJInWJek","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":22,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":10},"by_evidence_role":{"commentary":37},"count":37,"evidence_window":{"end":"2026-07-29","start":"2015-11-03"},"retrieval_snapshot":"2026-10-07T22:43:19.819916Z","timeline":[{"count":1,"week":"2015-W45"},{"count":1,"week":"2017-W23"},{"count":1,"week":"2018-W06"},{"count":1,"week":"2019-W39"},{"count":1,"week":"2020-W33"},{"count":1,"week":"2022-W10"},{"count":1,"week":"2023-W05"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2023-W15"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W40"},{"count":1,"week":"2023-W41"},{"count":1,"week":"2023-W52"},{"count":1,"week":"2024-W05"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W18"},{"count":2,"week":"2024-W29"},{"count":2,"week":"2024-W36"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W01"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W39"},{"count":2,"week":"2026-W02"},{"count":2,"week":"2026-W08"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W31"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Melanoma","slug":"melanoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Multicenter Selective Lymphadenectomy Trial II (MSLT-II)","A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node"],"brief_title":"Multicenter Selective Lymphadenectomy Trial II (MSLT-II)","collaborators":["National Institutes of Health (NIH)","National Cancer Institute (NCI)"],"conditions":["Melanoma"],"enrollment":{"count":1939,"type":"ACTUAL"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"Completion Lymphadenectomy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"},{"name":"Monitoring with nodal ultrasound","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"}],"nct_id":"NCT00297895","official_title":"A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node","overall_status":"COMPLETED","phase":["NA"],"primary_completion_date":{"date":"2019-09-30","type":"ACTUAL"},"primary_endpoints":[{"measure":"Melanoma-specific survival. This is defined as the time between the date of a subject's randomization (or date of CLND for those randomized to the CLND arm) and the date of death due to melanoma. Subjects are followed until death or 10yrs.","timeFrame":"10 years"}],"registry_last_updated":"2022-05-13","registry_url":"https://clinicaltrials.gov/study/NCT00297895","short_name":"MSLT-II","short_name_basis":"sponsor_study_id","sponsor":"Saint John's Cancer Institute","start_date":{"date":"2004-09-30","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, na","study_ids":[{"id":"MSLT-II","type":"sponsor_study_id"},{"id":"P01CA029605","type":"nih"},{"id":"R01CA189163","type":"nih"}],"study_type":"INTERVENTIONAL"}}}